Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

NCT00414388 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Sorafenib

Sponsor

Oncology Specialists, S.C.